國家衛生研究院 NHRI:Item 3990099045/15976
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 914264      線上人數 : 1341
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/15976


    題名: Development of a humanized antibody targeting extracellular HSP90alpha to suppress endothelial-mesenchymal transition-enhanced tumor growth of pancreatic adenocarcinoma cells
    其他題名: Development of a humanized antibody targeting extracellular HSP90α to suppress endothelial-mesenchymal transition-enhanced tumor growth of pancreatic adenocarcinoma cells
    作者: Fan, CS;Hung, HC;Chen, CC;Chen, LL;Ke, YY;Yeh, TK;Huang, CT;Chang, TY;Yen, KJ;Chen, CH;Chua, KV;Hsu, JTA;Huang, TS
    貢獻者: National Institute of Cancer Research;Institute of Biotechnology and Pharmaceutical Research
    摘要: Extracellular HSP90 alpha (eHSP90 alpha) is a promoter of tumor development and malignant progression. Patients with malignancies, including pancreatic ductal adenocarcinoma (PDAC), have generally shown 5 similar to 10-fold increases in serum/plasma eHSP90 alpha levels. In this study, we developed a humanized antibody HH01 to target eHSP90 alpha and evaluated its anticancer efficacy. HH01, with novel complementarity-determining regions, exhibits high binding affinity toward HSP90 alpha. It recognizes HSP90 alpha epitope sites (235)AEEKEDKEEE(244) and 251ESEDKPEIED260, with critical amino acid residues E237, E239, D240, K241, E253, and K255. HH01 effectively suppressed eHSP90 alpha-induced invasive and spheroid-forming activities of colorectal cancer and PDAC cell lines by blocking eHSP90 alpha's ligation with the cell-surface receptor CD91. In mouse models, HH01 potently inhibited the tumor growth of PDAC cell grafts/xenografts promoted by endothelial-mesenchymal transition-derived cancer-associated fibroblasts while also reducing serum eHSP90 alpha levels, reflecting its anticancer efficacy. HH01 also modulated tumor immunity by reducing M2 macrophages and reinvigorating immune T-cells. Additionally, HH01 showed low aggregation propensity, high water solubility, and a half-life time of >18 days in mouse blood. It was not cytotoxic to retinal pigmented epithelial cells and showed no obvious toxicity in mouse organs. Our data suggest that targeting eHSP90 alpha with HH01 antibody can be a promising novel strategy for PDAC therapy.
    日期: 2024-07-04
    關聯: Cells. 2024 Jul 04;13(13):Article number 1146.
    Link to: http://dx.doi.org/10.3390/cells13131146
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=2073-4409&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:001270398000001
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85198344089
    顯示於類別:[黃智興] 期刊論文
    [徐祖安] 期刊論文
    [葉燈光] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI001270398000001.pdf7587KbAdobe PDF39檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋